Your browser doesn't support javascript.
loading
Blood-based biomarker in Parkinson's disease: potential for future applications in clinical research and practice.
Tönges, Lars; Buhmann, Carsten; Klebe, Stephan; Klucken, Jochen; Kwon, Eun Hae; Müller, Thomas; Pedrosa, David J; Schröter, Nils; Riederer, Peter; Lingor, Paul.
Afiliación
  • Tönges L; Department of Neurology, Ruhr-University Bochum, St. Josef Hospital, Gudrunstr. 56, 44791, Bochum, Germany. lars.toenges@ruhr-uni-bochum.de.
  • Buhmann C; Center for Protein Diagnostics (ProDi), Ruhr University Bochum, 44801, Bochum, Nordrhein-Westfalen, Germany. lars.toenges@ruhr-uni-bochum.de.
  • Klebe S; Department of Neurology, University Medical Center Hamburg-Eppendorf, 20246, Hamburg, Germany.
  • Klucken J; Department of Neurology, University Hospital Essen, 45147, Essen, Germany.
  • Kwon EH; Department of Digital Medicine, University Luxembourg, LCSB, L-4367, Belval, Luxembourg.
  • Müller T; Digital Medicine Research Group, Luxembourg Institute of Health, L-1445, Strassen, Luxembourg.
  • Pedrosa DJ; Centre Hospitalier de Luxembourg, Digital Medicine Research Clinic, L-1210, Luxembourg, Luxembourg.
  • Schröter N; Department of Neurology, Ruhr-University Bochum, St. Josef Hospital, Gudrunstr. 56, 44791, Bochum, Germany.
  • Riederer P; Department of Neurology, St. Joseph Hospital Berlin-Weissensee, 13088, Berlin, Germany.
  • Lingor P; Department of Neurology, Universitätsklinikum Gießen and Marburg, Marburg Site, 35043, Marburg, Germany.
J Neural Transm (Vienna) ; 129(9): 1201-1217, 2022 09.
Article en En | MEDLINE | ID: mdl-35428925
ABSTRACT
The clinical presentation of Parkinson's disease (PD) is both complex and heterogeneous, and its precise classification often requires an intensive work-up. The differential diagnosis, assessment of disease progression, evaluation of therapeutic responses, or identification of PD subtypes frequently remains uncertain from a clinical point of view. Various tissue- and fluid-based biomarkers are currently being investigated to improve the description of PD. From a clinician's perspective, signatures from blood that are relatively easy to obtain would have great potential for use in clinical practice if they fulfill the necessary requirements as PD biomarker. In this review article, we summarize the knowledge on blood-based PD biomarkers and present both a researcher's and a clinician's perspective on recent developments and potential future applications.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: J Neural Transm (Vienna) Año: 2022 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: J Neural Transm (Vienna) Año: 2022 Tipo del documento: Article País de afiliación: Alemania